My guess is they are releasing the results of the Her-Vaxx trial that has just finished.
I can't post the link but if you google Her-Vaxx trial results it's on the first page.
Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)
HER-Vaxx plus standard chemotherapy improves the OS benefit and reduces tumor burden, which correlates with vaccine-induced immune response, and exhibits a favorable safety profile compared to standard-of-care chemotherapy alone. HER-Vaxx vaccine is suggested as a first-in-class immunotherapy in combination with standard chemotherapy.
IMU Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)